PTCT, US69366J2006

Truist sets USD 62.00 target for PTC Therapeutics stock

Published on 10/17/2026 at 19:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 360.52 million on July 30, 2026. PTC Therapeutics stock last traded at USD 59.24 on October 16, 2026, down 2.87 percent on Nasdaq.

Analyst view and trading dates

Truist Financial began coverage with a USD 62.00 target on October 16, 2026.
Second-quarter 2026 revenue reached USD 360.52 million.
PTC Therapeutics stock last traded at USD 59.24 on October 16, 2026, down 2.87 percent on Nasdaq.
PTC Therapeutics plans to report third-quarter 2026 results on October 29, 2026.

PTCT, US69366J2006, Illustration mit AI erstellt.

Truist Financial initiated coverage of PTC Therapeutics on October 16, 2026, with a Hold rating and a USD 62.00 price target, which stood 4.66 percent above the Nasdaq price. The assessment was reported by MarketBeat. PTC Therapeutics was last at USD 59.24 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.87 percent from the prior close of USD 60.99.

Revenue sets the operating backdrop

PTC Therapeutics reported USD 360.52 million in revenue for the second quarter of 2026, up 101.50 percent from the same period a year earlier. The figure also exceeded the USD 298.63 million consensus estimate by 20.73 percent. Quarterly earnings per share came to USD 0.92 against consensus of USD 0.24, according to MarketBeat.

Stock sits near its yearly low

The Nasdaq price stood USD 0.44, or 0.75 percent, above the 52-week low of USD 58.80 on October 16, 2026. It was USD 31.63, or 34.81 percent, below the 52-week high of USD 90.87. Trading volume reached 787,612 shares, compared with an average volume of 1,121,887 shares.

On September 21, 2026, PTC Therapeutics completed its acquisition of the ST-920 Fabry disease gene therapy program from Sangamo Therapeutics, according to the company's investor-relations release. The company's latest investor-relations materials identify second-quarter 2026 results as the latest quarterly report.

What date comes next?

PTC Therapeutics is scheduled to report third-quarter 2026 financial results on October 29, 2026, at 4:30 p.m. ET, according to PTC Therapeutics. The company reported USD 1.05 billion in cash and cash equivalents at June 30, 2026, while operating cash flow for the second quarter was USD 129.11 million.

Comparison with peers

PTC Therapeutics (Nasdaq, USD): minus 2.87 percent, P/E -102.14, market capitalization USD 4.9 billion
Vertex Pharmaceuticals (Nasdaq, USD): minus 1.77 percent, P/E 29.09, market capitalization USD 126.7 billion
Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E -5.90, market capitalization USD 1.8 billion

Price remains close to the low

PTC Therapeutics had a market capitalization of USD 4.9 billion and a trailing price-to-earnings ratio of -102.14 on October 16, 2026. Its 52-week range was USD 58.80 to USD 90.87, putting the last Nasdaq price near the lower end of that interval.